ข่าวประชาสัมพันธ์ Press Releases ข่าวย้อนหลัง หัวข้อข่าว บลอก

Britannia Pharmaceuticals Ltd: Phase 3 TOLEDO Study Shows Apomorphine Infusion Provides Effective Relief of Persistent Motor Fluctuations in Parkinson#s Disease (PD) Patients Whose Symptoms are Uncontrolled With Oral Medication

Food and Healthcare Press Releases วันจันทร์ที่ ๖ สิงหาคม พ.ศ. ๒๕๖๑ ๑๑:๒๕ น.
ขนาดตัวอักษร: ใหญ่ กลาง เล็ก
LONDON--6 Aug--PRNewswire/InfoQuest
Britannia Pharmaceuticals Ltd has announced publication of the results of the double-blind phase of the TOLEDO study in Lancet Neurology[1].

Treatment with APO-go(R)/MOVAPO(R) (apomorphine) subcutaneous infusion for 12 weeks gave significantly greater reductions in OFF time (periods when PD medications don't work) from baseline compared with placebo: -2.47 h/day versus -0.58 h/day, respectively - a treatment difference of almost 2 hours (p=0.0025) and double the change in OFF time recognised as meaningful to PD patients. These reductions were seen in the first week of treatment with APO-go(R)/MOVAPO(R) infusion.

Compared with placebo, significantly greater increases in ON time (periods with good motor control) without troublesome dyskinesia - 'good' ON time - from baseline were observed with APO-go(R)/MOVAPO(R) infusion: 2-77 h/day versus 0-80 h/day, respectively (p=0-0008), and patients could also reduce the dosage and number of administrations of concomitant oral PD medications significantly (p=0.0014).

APO-go(R)/MOVAPO[(R)/] infusion is an established therapy for PD, a disease characterised by progressive degeneration of dopamine-containing neurons in the brain, resulting in loss of motor control. TOLEDO is the first multicentre, randomised, double-blind trial to investigate its efficacy and safety in PD and was undertaken in 107 patients from 23 hospitals in 7 countries whose symptoms were uncontrolled despite taking multiple medications.

Clinical improvements were reflected in patients' assessment of treatment: significantly more APO-go(R)/ MOVAPO(R) infusion patients rated themselves as 'improved' (71%) versus placebo (18%; p<0.0001).
Professor Regina Katzenschlager, lead investigator of TOLEDO, commented:

"TOLEDO is an important addition to our knowledge, providing Level 1 evidence for the first time and confirming previous observational studies. Apomorphine infusion is effective and well tolerated by patients experiencing debilitating treatment response fluctuations despite optimised treatment."

Professor Andrew Lees, an investigator in the pivotal clinical trial that led to apomorphine being licensed for PD treatment in the UK, added:
"We hope the positive results of the TOLEDO study will help ensure apomorphine infusion, which is delivered using a small, ambulatory mini-pump, is incorporated into national PD treatment guidelines."
The TOLEDO study is sponsored by Britannia Pharmaceuticals Ltd., part of the STADA Arzneimittel AG group of companies and manufacturer of apomorphine products.
Founded in 1982, Britannia Pharmaceuticals Limited is a pharmaceutical company based in Reading, UK, specialising in the neurology market.
Britannia is owned by Frankfurt-based STADA Arzneimittel AG.

APO-go(R) products are marketed in the UK by Britannia Pharmaceuticals Ltd and transferred with the acquisition of Britannia into the STADA portfolio in 2007. APO-go(R) products are marketed outside the UK through own affiliates and licensing partners.

For information about:
Britannia Pharmaceuticals Ltd:
http://www.britannia-pharm.com
TOLEDO study:
https://www.clinicaltrials.gov/ct2/show/NCT02006121?term=NCT02006121&rank=1
For the APO-go(R) infusion SmPC:
https://www.medicines.org.uk/emc/product/3908/smpc
[1]Katzenschlager R, et al. Lancet Neurology, 2018. Published online July 25, 2018   http://dx.doi.org/10.1016/S1474-4422(18)30239-4
Source: Britannia Pharmaceuticals Ltd

ขนาดตัวอักษร: ใหญ่ กลาง เล็ก

ข่าวประชาสัมพันธ์ที่เกี่ยวข้อง

AsiaNet Daily Summary – Press Releases from Friday February 28 until Monday March 3

OBESITY DRUG... MELBOURNE: Metabolic Pharmaceuticals said early results show obesity drug AOD9604 is safe, with trial participants losing an average of half a kilo in a week. www.metabolic.com.au COCHLEAR IMPLANTS... BEIJING: A new parents resouce centre ...

Phase II Placebo-Controlled Study of V-1 Immunitor in VACCINE Journal

Researchers of Thailand-based Immunitor company announce the publication of results of placebo-controlled, Phase II clinical trial entitled 'V-1 Immunitor: oral therapeutic AIDS vaccine with prophylactic potential' in January 30, 2003 issue of VACCINE – t...

AsiaNet Daily Summary – Press Releases for Friday January 3

NEW TREATMENT... ALDERLEY PARK: A potential new treatment for people suffering from manic depression has been submitted to the U.S. Food and Drug Administration (FDA) for approval, a press release said. CHINESE EXPANSION... HONG KONG: International law fi...

หัวข้อข่าวที่เกี่ยวข้อง

หัวข้อข่าวยอดนิยม

กรมสรรพากร ธนาคารกรุงเทพ ธนาคารกรุงไทย ธนาคารออมสิน ไปรษณีย์ไทย การบินไทย ธนาคารกสิกรไทย hotmai เพียวริคุ jobbkk ธนาคารไทยพาณิชย์ คาราบาว ดีแทค ไทยพาณิชย์ แจ่มใส เมเจอร์ ธนาคารอาคารสงเคราะห์ 12car กรุงไทย ธนาคารกรุงศรีอยุธยา กระทรวงสาธารณสุข การรถไฟแห่งประเทศไทย มิตซูบิชิ เมืองทอง ธนาคารทหารไทย ตลาดหลักทรัพย์แห่งประเทศไทย ซัมซุง มาม่า วันทูคอล ธนาคารแห่งประเทศไทย กระทรวงพาณิชย์ เวลาประเทศไทย ปตท ธอส บิ๊กซี กรมอุตุ กรมศุลกากร แม็คโคร ธนาคารกรุงศรี กระทรวงการคลัง